La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Novo Nordisk Gestion

Gestion contrôle des critères 3/4

Le PDG Novo Nordisk's est Lars Jorgensen, nommé en Jan2017, a un mandat de 7.58 ans. détient directement 0.002% des actions de la société, d'une valeur de DKK 84.17M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.5 ans et 6.4 ans.

Informations clés

Lars Jorgensen

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	7.6yrs
Propriété du PDG	0.002%
Durée moyenne d'occupation des postes de direction	3.5yrs
Durée moyenne du mandat des membres du conseil d'administration	6.4yrs

Mises à jour récentes de la gestion

Recent updates

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

May 04

The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Apr 28

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Apr 14

Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Mar 18

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Dec 30

Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Dec 12

Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Nov 24

Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Aug 20

These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Aug 02

Analyse de la rémunération des PDG

Comment la rémunération de Lars Jorgensen a-t-elle évolué par rapport aux bénéfices de Novo Nordisk?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	DKK 90b
Mar 31 2024	n/a	n/a	DKK 89b
Dec 31 2023	n/a	n/a	DKK 84b
Sep 30 2023	n/a	n/a	DKK 75b
Jun 30 2023	n/a	n/a	DKK 67b
Mar 31 2023	n/a	n/a	DKK 61b
Dec 31 2022	DKK 60m	DKK 17m	DKK 56b
Sep 30 2022	n/a	n/a	DKK 53b
Jun 30 2022	n/a	n/a	DKK 51b
Mar 31 2022	n/a	n/a	DKK 49b
Dec 31 2021	DKK 58m	DKK 17m	DKK 48b
Sep 30 2021	n/a	n/a	DKK 46b
Jun 30 2021	n/a	n/a	DKK 44b
Mar 31 2021	n/a	n/a	DKK 43b
Dec 31 2020	DKK 57m	DKK 14m	DKK 42b
Sep 30 2020	n/a	n/a	DKK 42b
Jun 30 2020	n/a	n/a	DKK 41b
Mar 31 2020	n/a	n/a	DKK 40b
Dec 31 2019	DKK 55m	DKK 14m	DKK 39b
Sep 30 2019	n/a	n/a	DKK 39b
Jun 30 2019	n/a	n/a	DKK 38b
Mar 31 2019	n/a	n/a	DKK 38b
Dec 31 2018	DKK 41m	DKK 11m	DKK 39b
Sep 30 2018	n/a	n/a	DKK 38b
Jun 30 2018	n/a	n/a	DKK 39b
Mar 31 2018	n/a	n/a	DKK 39b
Dec 31 2017	DKK 32m	DKK 9m	DKK 38b

Rémunération vs marché: Données insuffisantes pour établir si la rémunération totale de Lars est raisonnable par rapport à des entreprises de taille similaire sur le marché Danish.

Rémunération et revenus: La rémunération de Lars a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Lars Jorgensen (58 yo)

7.6yrs

Titularisation

DKK 60,100,000

Compensation

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Lars Jorgensen	President	7.6yrs	DKK 60.10m	0.0021% DKK 84.2m
Karsten Knudsen	Executive VP	6.5yrs	DKK 21.50m	0.000010% DKK 402.7k
Henrik Wulff	Executive VP of Product Supply	no data	DKK 22.00m	0.000060% DKK 2.4m
Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	no data	DKK 21.30m	pas de données
Martin Lange	Executive VP of Development & Member of the Management Board	3.6yrs	DKK 20.90m	pas de données
Marcus Schindler	EVP of Research & Early Development	3.4yrs	DKK 20.90m	pas de données
Maziar Doustdar	Executive VP of International Operations & Member of the Management Board	no data	pas de données	0.0011% DKK 45.5m
Douglas Langa	Executive VP of North America Operations & Member of Management Board	no data	pas de données	pas de données
Ludovic Helfgott	Executive VP	no data	pas de données	pas de données
Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	1.4yrs	pas de données	pas de données
David Moore	Executive VP of Corporate Development & Member of Management Board	1.4yrs	pas de données	pas de données
Daniel Bohsen	CVP & Head of Investor Relations	no data	pas de données	pas de données

3.5yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Gestion expérimentée: L'équipe de direction de NOVO B est considérée comme expérimentée (ancienneté moyenne 3.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Sylvie Gregoire	Independent Director	9.4yrs	DKK 1.80m	pas de données
Helge Lund	Independent Chairman of the Board	7.4yrs	DKK 3.10m	pas de données
Henrik Poulsen	Vice Chairman of the Board	3.4yrs	DKK 2.00m	pas de données
Laurence Debroux	Independent Director	5.4yrs	DKK 2.00m	pas de données
Martin MacKay	Independent Director	6.4yrs	DKK 1.70m	pas de données
Andreas Fibig	Independent Director	6.4yrs	DKK 1.40m	pas de données
Kasim Kutay	Non-Independent Director	7.4yrs	DKK 1.20m	pas de données
Christina Law	Independent Director	2.4yrs	DKK 1.30m	pas de données
Liselotte Hyveled	Employee Representative Director	2.4yrs	DKK 800.00k	0% DKK 0
Mette Jensen	Employee Non-Independent Representative Director	6.4yrs	DKK 1.20m	pas de données
Thomas Rantzau	Employee Representative Non-Independent Director	6.6yrs	DKK 1.00m	pas de données
Elisabeth Christensen	Employee Representative Director	2.4yrs	DKK 800.00k	pas de données

6.4yrs

Durée moyenne de l'emploi

58.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de NOVO B sont considérés comme expérimentés (ancienneté moyenne 6.4 ans).

Novo Nordisk Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Employee Representative Director recently sold kr.7.6m worth of stock

Key Executive recently sold kr.50m worth of stock

President recently sold kr.145m worth of stock

Insider recently sold kr.10m worth of stock

Recent updates

Employee Representative Director recently sold kr.7.6m worth of stock

Now 20% undervalued after recent price drop

Second quarter 2024 earnings: EPS misses analyst expectations

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

Key Executive recently sold kr.50m worth of stock

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Final dividend of kr.6.40 announced

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Price target increased by 14% to kr.887

President recently sold kr.145m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Insider recently sold kr.10m worth of stock

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Price target increased by 7.6% to kr.672

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 16%

These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen